% | $
Quotes you view appear here for quick access.

Isis Pharmaceuticals, Inc. Message Board

  • eai_specialist eai_specialist Oct 31, 2012 4:35 PM Flag

    Zacks Research: ISIS near term target @ $11

    ...While the company’s stock has fallen 27 percent in the past three months, Zacks upgraded shares of Isis Pharmaceuticals from a neutral rating to an outperform rating on Tuesday with a price target of $11. Zacks’ analyst wrote “We believe that antisense technology (the main area of focus at Isis) represents an exciting and potentially revolutionary platform for developing therapeutic candidates to treat a wide margin of diseases.”

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
67.80+0.63(+0.94%)2:56 PMEDT